CEO bullish on drug for rare disease despite concerns
December 01, 2015 at 13:14 PM EST
BioMarin Pharmaceuticals' CEO is still optimistic about FDA approval of its Duchenne muscular dystrophy drug, drisapersen, despite FDA concerns.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|